New data from the PROCLIPI study has shown a meaningful overall survival benefit for patients with advanced cutaneous T-cell ...
ENA Respiratory has raised US$22.4m (AU$34m) in Series B financing to support the phase 2 clinical development of its nasal spray therapy, INNA-051. The Melbourne-based pharmaceutical company welcomed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback